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Answer: B  
 
Brugada Syndrome (BrS) is a rare autosomal 
dominant entity with variable penetrance 
and is caused by a mutation in the cardiac 
sodium channels (1). BrS has 3 subtypes 
with type 1 (ECG presented) being the most 
common; it is described as an elevation in 
the J point and coved-type ST segment 
elevation of >2 mm followed by an inverted 
T wave, with this feature being present in> 1 
right precordial lead (V1 through V3) (2, 3). 
To increase the sensitivity of diagnosing 
BrS, the expert consensus statement of 2013 
on inherited arrhythmogenic diseases (4) 
recommend diagnosis just based on ECG 
change in only one precordial lead without 
any clinical symptoms (excluding electrolyte 
abnormality, myocardial infarction and 
pulmonary embolism). The prevalence of 
BrS is not quite known but is estimated at 5-
20 per 10,000 people (1). Patients may 
suffer from syncope and/or sudden cardiac 
death (SCD) due to polymorphic ventricular 
tachycardia (VT)/ventricular fibrillation 
(VF) (2). It is estimated that spontaneous 
type 1 Brugada pattern is associated with 
0.5-1% event rate per year, with that event 
rate going as high as 60% over the next 4 
years in those with prior cardiac arrest or 
arrhythmic events (1-3). Implantable 
cardioverter defibrillator (ICD) is not 
indicated in asymptomatic patients while its 
implantation is class I indication in those 
with aborted cardiac arrest. The 
management of those with spontaneous 
asymptomatic Brugada syndrome (such as in 
the case of our patient) including 
electrophysiological (EP) studies, remains 
controversial (1-3). Asymptomatic patients 
do not require antiarrhythmic therapy. 
Quinidine, a class I antiarrhythmic, has been 
shown to suppress ventricular arrhythmias in 
BrS patients. It’s mainly used in those with 
multiple ICD shocks, those who have 
contraindication to ICD therapy and in BrS 
patients with supraventricular arrhythmias 
(4). This patient underwent an EP study 
without any inducible ventricular 
arrhythmias. He did not require an ICD 
placement and is now being closely 
followed up.  
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